Foundayo and Stomach Pain: What Is Normal and What Is Not

Stomach discomfort on Foundayo is common. Digestive side effects with Foundayo can include nausea, vomiting, diarrhoea, constipation, indigestion and abdominal pain. They are particularly common during dose escalation and often become less frequent over time. For UK adults taking or considering Foundayo (orforglipron) for weight management, these symptoms are most likely in the first weeks and after a dose increase.

There is one important exception, and it is the reason this page exists. Severe, persistent abdominal pain that goes through to your back, especially with nausea and vomiting, is not normal adjustment. That pattern needs urgent medical attention the same day because, although rare, it can signal a serious problem such as pancreatitis. The MHRA strengthened its warnings on this in January 2026.

Key things to know

• Digestive side effects are the common ones with Foundayo : nausea, vomiting, diarrhoea, constipation, bloating and mild cramping.
• They usually appear when treatment starts and after each dose increases, and often settle as your body adjusts.
• Severe, persistent abdominal pain radiating to the back, with or without nausea and vomiting, needs urgent medical attention. Do not wait to see if it passes.
• On 29 January 2026 the MHRA strengthened warnings across GLP-1 and dual GLP-1/GIP receptor agonist medicines about severe acute pancreatitis, including rare reports of necrotising and fatal cases.
• Between 2007 and October 2025 the MHRA received 1,296 UK reports of pancreatitis linked to this class, including 19 fatal cases and 24 cases of necrotising pancreatitis, against roughly 25.4 million packs dispensed in the past five years.
• If pancreatitis is suspected, treatment is stopped straight away. If it is confirmed, it is not restarted.
• If you obtain Foundayo privately, do not assume every clinician involved in your care will automatically have a record of it. Tell them you are taking it, particularly if you are being assessed for abdominal symptoms.
• Suspected side effects can be reported through the MHRA Yellow Card scheme.

The two kinds of stomach pain, side by side

People asking this question want one thing: is what I am feeling normal. This table answers it directly.

If your pain sits in the right hand column, stop reading and get medical help. Nothing further down this page is more important than that.

Why Foundayo affects your stomach at all

Foundayo is the brand name for orforglipron, a GLP-1 receptor agonist authorised by the MHRA on 10 August 2026, GLP-1 receptor agonists are used for weight loss and type 2 diabetes management. GLP-1 is a hormone your gut releases after eating. Medicines in this class switch on the same receptors, so the body responds as though more of that hormone were present.

Foundayo is taken daily, with no food or water restrictions, which reflects its role in obesity treatment.

One of the things that hormone does is slow gastric emptying, meaning food stays in your stomach longer.

Orforglipron delays gastric emptying, and gastrointestinal side effects are among its most common adverse effects. The two may be related, but not every digestive symptom should be assumed to be caused by delayed gastric emptying. The fullness you feel after a small meal and the nausea you feel when you eat past it come from the same mechanism.

Feeling full sooner can occur with treatment and may contribute to reduced food intake. But a new, severe or persistent abdominal symptom should not be dismissed simply because the medicine affects appetite and digestion.

What ordinary adjustment feels like

Adjustment discomfort is mild to moderate, tied to eating, and it eases over days to weeks rather than building.

People commonly describe a heavy or overful feeling after meals that used to be comfortable, mild cramping, wind and bloating, queasiness that comes in waves, and a bowel habit that has shifted in one direction or the other. This kind of upset stomach is a common Foundayo issue, and stomach pain with indigestion affected about 13% to 16% of users taking Foundayo . Some people get all of it. Some get almost none. Results and tolerance vary between individuals.

When do Foundayo side effects start?

Usually within the first days of starting, and again within a few days of any dose increase. That pattern is a useful clue. Symptoms that track the timing of a change are behaving the way adjustment behaves. Symptoms that arrive out of nowhere, weeks into a stable dose, deserve more attention rather than less.

How long do Foundayo side effects last?

For many people, gastrointestinal symptoms become less frequent as treatment continues. If symptoms are severe, persistent or interfere with eating and drinking, contact your prescriber rather than simply waiting for them to settle.

Two situations are not simple adjustments. Symptoms that are still severe after several weeks, and symptoms that are stopping you eating or drinking normally, both need a conversation with your prescriber. Enduring something that is preventing you from keeping fluids down is not patience. It is a problem that has been left too long.

The pain that is not adjustment: acute pancreatitis

Acute pancreatitis is inflammation of the pancreas and is an uncommon but serious adverse reaction associated with GLP-1 receptor agonists. With Foundayo , the prescribing information advises patients to seek immediate medical attention for persistent, severe abdominal pain, particularly when it may radiate to the back or occur with nausea or vomiting. Foundayo should be discontinued if pancreatitis is suspected and should not be restarted if the diagnosis is confirmed.

The healthcare products regulatory agency in the UK advises patients to be vigilant about these symptoms and to seek help without delay.

What the MHRA has said

On 29 January 2026 the MHRA issued strengthened warnings across GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, emphasising the risk of severe acute pancreatitis, including rare reports of necrotising and fatal cases.

The figures behind that decision are worth seeing, because they let you judge the risk rather than guess at it. Between 2007 and October 2025, the MHRA received 1,296 UK reports of pancreatitis associated with this class of medicine. Of those, 19 were fatal and 24 involved necrotising pancreatitis, a form in which pancreatic tissue dies. Over the past five years, roughly 25.4 million packs of these medicines were dispensed in the UK, and around 1.6 million UK adults used a GLP-1 medicine for weight management between early 2024 and 2025.

So the event is rare against the number of people treated. It is also severe enough, when it happens, that the regulator acted. Both halves of that sentence are true and neither cancels the other. The practical message is to recognise the warning symptoms and seek urgent medical assessment rather than assuming severe pain is ordinary indigestion.

How the pain is different

The MHRA describes the warning sign as severe, persistent stomach pain that may radiate to the back and may be accompanied by nausea and vomiting.

Take each part of that seriously. Severe means it dominates your attention rather than nags. Persistent means it does not come and go with meals. Radiating to the back is the detail people often fail to mention to a clinician, and it is one of the characteristic features.

What happens if pancreatitis is suspected

Treatment is stopped immediately if acute pancreatitis is suspected. If it is confirmed, the medicine is not restarted at all.

That second point is not a pause. It is permanent, and it applies to the class rather than to one product. Anyone with a history of pancreatitis should also expect caution before being prescribed a medicine in this group, which is one of the reasons the consultation asks about it.

Gallbladder problems and how they feel

Acute gallbladder disease has been reported with GLP-1 receptor agonists, including orforglipron, and gallbladder events were associated with weight reduction in the product information.

Gallbladder pain has a recognisable shape. It typically sits in the upper right of the abdomen, under the ribs, sometimes spreading to the right shoulder blade. It often comes on after a fatty meal, builds steadily over minutes, holds for anything from half an hour to several hours, then fades. Nausea, constipation, and diarrhea often come with it.

Seek medical advice if that pattern is happening to you. Seek urgent help if the pain comes with a fever, with yellowing of the skin or the whites of the eyes, or if it does not settle at all.

What to do with the pain you have

Work through this in order.

1. Is the pain severe and persistent, particularly going through to your back, with nausea or vomiting? Seek urgent medical attention today. Do not take another dose.
2. Is there fever, yellowing of the skin or eyes, blood in your vomit, or black tarry stools? Seek urgent medical attention.
3. Are you repeatedly vomiting or unable to keep fluids down? Contact a healthcare professional promptly, particularly if you are becoming dizzy, weak or are passing much less urine.
4. Is the pain moderate, linked to meals, and easing between them? This fits adjustment. Use the management steps below and raise it at your next review.
5. Has it been several weeks and it is not improving? Contact your prescriber rather than waiting for the next scheduled review.

Managing everyday digestive side effects

None of this replaces advice from your prescriber, and none of it applies to the urgent symptoms above.

A note on vomiting. Occasional nausea that passes is one thing. Repeated vomiting is not something to push through, both because of dehydration and because persistent vomiting alongside severe pain is part of the urgent picture described above. Vomiting affected 13% to 24% of users during treatment.

Missed doses

If you miss a dose of Foundayo , take it as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and take your next dose on the usual day.

Do not take two doses on the same day to make up for a missed dose. If you are unsure what to do, check the patient information leaflet or speak to your pharmacist or prescriber.

Dehydration is the complication people overlook

Dehydration is easy to overlook when appetite is reduced and nausea, vomiting or diarrhoea are taking place at the same time. If you are struggling to drink enough or are losing fluids through vomiting or diarrhoea, do not simply wait for it to pass. Contact your healthcare professional, particularly if you have kidney problems.

Tell every clinician that you take it

This is the practical point that pages on side effects tend to leave out, and the MHRA has made it explicitly.

Privately prescribed weight management medicines may not appear on your medical record. That means a clinician assessing your abdominal pain, whether in an urgent care setting or at an appointment, may have no idea you are taking a GLP-1 medicine unless you say so.

Say so every time, without waiting to be asked. Carry the name Foundayo written down or on your phone. When you describe your pain, mention the medicine in the first sentence, because it changes what the clinician considers first.

Mentioning Foundayo early gives the clinician an important piece of information when assessing your symptoms.

When to stop taking Foundayo

Stopping is a decision for your prescriber, with one exception. If you have severe, persistent abdominal pain of the kind described above, do not take another dose and seek urgent medical attention. In that situation, waiting for a scheduled appointment is the wrong call.

Outside that, do not stop or change your treatment on your own. Ordinary side effects are usually managed rather than a reason to abandon treatment, and your prescriber or healthcare provider may adjust your treatment plan instead of stopping altogether. Bring what you are experiencing to a review: what the symptom is, when it started, how it relates to meals and doses, and what you have already tried.

Medical Disclaimer

This article is general information about prescription only medicine and is not medical advice. It does not replace an assessment by a qualified healthcare professional who knows your medical history, and it should not be used to diagnose the cause of your own symptoms. Foundayo contains the active ingredient orforglipron and should only be used under the supervision of an appropriately qualified prescriber, and results and tolerance vary between individuals.

Always read the patient information leaflet supplied with your medicine and follow your prescriber's instructions. Seek urgent medical attention for severe or persistent abdominal pain, particularly if it radiates to the back or is accompanied by ongoing vomiting. Seek urgent help for symptoms of a serious allergic reaction, such as difficulty breathing or swelling of the face or throat. If you cannot keep fluids down or develop signs of significant dehydration, contact a healthcare professional promptly. Suspected side effects can be reported through the MHRA Yellow Card scheme.